RUBY - Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers

Rubius Therapeutics (RUBY) presents new preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of human papillomavirus ((HPV)) 16-positive cancers at the Federation of Clinical Immunology Societies ((FOCIS)) Virtual Annual Meeting.The data demonstrated the dual mechanism of action of RTX-321 and its mouse surrogates to function as an aAPC to boost HPV 16 E7-specific CD8+ T-cell responses and promote HPV 16-independent stimulation of innate (NK cells) and adaptive immune (non-HPV antigen-specific CD8+ T cells) responses.Mouse surrogates of RTX-321 promote tumor control, memory formation and epitope spreading in tumor models in vivoTreatment with the RTX-321 mouse surrogate results in minimal, reversible effects in vivo (body weight change, IFN? and ALT levels) due to the biodistribution to the vasculature and spleen. These findings support the potential of RTX-321 as an effective therapy for the treatment of HPV 16+ cancers.

For further details see:

Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers